Last reviewed · How we verify
NCT06882330: NeuroDBT
Neural Mechanisms of Dialectical Behavioral Therapy in Patients with Borderline Personality Disorder
NA trial testing Dialectical behavior therapy in Borderline Personality Disorder in 106 participants. Completed in 15 August 2023.
10 August 2023
Quick facts
| Lead sponsor | Masarykova Univerzita |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 106 |
| Start date | 27 August 2020 |
| Primary completion | 10 August 2023 |
| Estimated completion | 15 August 2023 |
| Sites | 1 location across Czechia |
Drugs / interventions tested
- Dialectical behavior therapy
Conditions studied
- Borderline Personality Disorder — all drugs for Borderline Personality Disorder →
Sponsor
Masarykova Univerzita
Who can join
16 and older, any sex, with Borderline Personality Disorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research examines the behavioral and neural mechanisms of dialectical behavior therapy (DBT) effect in patients with borderline personality disorder (BPD).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06882330
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Dialectical behavior therapy
Trials testing the same drug.
- NCT05741268 — Effect of Dialectical Behavior in Patients With Bipolar Disorder · NA · completed
- NCT04094623 — The Muti-centered Investigation，Pathogenesis and Intervention Study of Non-suicidal Self-injury Behavior in China · NA · unknown
- NCT02134223 — Methylation Status of BDNF Gene After Dialectical Behavior Therapy in BPD · NA · completed
Other recruiting trials for Borderline Personality Disorder
Currently open trials in the same condition.
- NCT06458933 — Testing Interventions for Borderline Personality Disorder. · Phase 2 · recruiting
- NCT07001475 — A Study to Test How BI 3031185 is Tolerated by People With Borderline Personality Disorder or Attention-deficit/Hyperact · Phase 1 · recruiting
- NCT07119541 — Testing an Alliance-Focused Dialectical Behaviour Therapy Training for Borderline Personality Disorder · NA · active not recruiting
- NCT06446765 — Mindfulness-based Neurofeedback to Augment Psychotherapy for Adults With Borderline Personality Disorder · Phase 2 · recruiting
- NCT07197502 — Treatment of Borderline Personality Disorder With rTMS · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06882330 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Masarykova Univerzita
- Last refreshed: 18 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06882330.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing